TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04641429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Description: Participants in the experimental group receive 12-week group-based Qigong exercise training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Participants in the control group receive 12-week group-based stretching exercise training.
Study: NCT00343980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, 4 mg once or twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg almorexant
Study: NCT00343980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: Tablets, 4 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 4 mg/day.
Study: NCT03731754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Closure
Description: Primary closure discontinuously the perineal wound of APR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cross closure
Description: Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
Study: NCT00495261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-enhanced cognitive behavioural therapy (MCBT)
Description: a variation of cognitive behavioural therapy (CBT)
Study: NCT04152629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg almorexant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem
Study: NCT04152629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
Study: NCT04272775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study: NCT00495261

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation-enhanced cognitive behavioural therapy (RCBT)
Description: a variation of cognitive behavioural therapy (CBT)
Study: NCT03847389

Intervention type: DRUG
Group type: OTHER
Intervention: Clobetasol propionate 0.05% Topical Oil
Description: thin film application of the oil twice daily
Study: NCT02131155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Once daily
Study: NCT04557930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hopewell Hospitalist Video Game
Description: Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
Study: NCT04174248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCSMS App
Description: Breast Cancer Using a Self-Management Support mHealth Application
Study: NCT01019044

Intervention type: PROCEDURE
Intervention: Rectal mucosa biopsy
Description: Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
Study: NCT00529490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic lactate
Description: Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
Study: NCT01221948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Rechargeable Deep Brain Stimulation System
Study: NCT03825783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L201
Description: CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
Study: NCT00529750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRBESARTAN
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Tablets
Study: NCT00079001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: androgen deprivation therapy
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium supplement
Description: Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
Study: NCT01595568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
Study: NCT03125005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow Universal Pulse Oximeter Sensor
Study: NCT03835325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cogmax®
Description: Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
Study: NCT02280239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem
Study: NCT02280239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
Study: NCT02591134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Nutritive Sweetened Beverages
Description: Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
Study: NCT00522626

Intervention type: DEVICE
Intervention: Maternal fetal monitoring
Description: Simultaneous monitoring of maternal and fetal physiology
Study: NCT03337646

Intervention type: DRUG
Group type: OTHER
Intervention: Lisdexamfetamine Dimesylate
Description: Medication to treat ADHD
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem
Study: NCT03829124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 10mg/ml IV push slowly 0.5-2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 10mg/ml IV push slowly 0.5-2mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
Study: NCT01987739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg zolpidem
Study: NCT02239380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study.
Study: NCT02680548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine hydrochloride injectable suspension USP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine hydrochloride injectable suspension USP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg/cc methylprednisolone acetate injectable suspension USP
Study: NCT04534257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION Sirolimus DCB
Description: Suitable lesions will be treated with SELUTION Sirolimus DCB
Study: NCT02686034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore-S
Description: At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore-S Sham
Description: At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
Study: NCT00606190

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde brain perfusion
Description: observational

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade brain perfusion
Description: observational
Study: NCT02636270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex
Description: Treat PAPP-A2 deficient patients with Increlex
Study: NCT04849286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878
Description: Oral solution
Study: NCT03323879

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDR/HDR
Description: Focal LDR to dominant lesion with whole gland 19 Gy HDR
Study: NCT02613104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotion recognition modification - sad>happy
Description: Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: emotion recognition modification - sad>happy control
Description: Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotion recognition modification - angry>happy
Description: Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: emotion recognition modification - angry>happy control
Description: Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
Study: NCT04462666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huzhang granule
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huzhang granule Placebo
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huzhang granule Placebo
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib Placebo
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoricoxib Placebo
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.
Study: NCT01690091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformini hydrochloridum (Siofor 1000 tbl, Berlin)
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformini hydrochloridum (Siofor 1000 tbl, Berlin)
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
Study: NCT03497650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Education of Strengthening.
Description: Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Education of Strengthening.
Description: Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
Study: NCT01833143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir